In preclinical investigation, determining an accurate Melanotan dose requires a precise understanding of melanocortin receptor affinity, molecular weight, and volumetric dilution. This technical guide outlines published research parameters, receptor binding profiles, reconstitution calculations, and analytical quality verification standards for laboratory research use only.
In preclinical investigation, determining an accurate Melanotan dose requires a precise understanding of melanocortin receptor affinity, molecular weight, and volumetric dilution. This technical guide outlines published research parameters, receptor binding profiles, reconstitution calculations, and analytical quality verification standards for laboratory research use only.
In published literature, a preclinical Melanotan dose typically ranges from 0.5 µg/kg to 10 µg/kg in mammalian rodent models, or 1 nM to 100 nM in in vitro cell culture assays, depending on receptor selectivity and tissue expression targets. These experimental protocols evaluate systemic melanocortin pathway activation rather than clinical outcomes.
Establishing rigorous quantitative controls is essential when evaluating synthetic melanocortin peptides in laboratory environments. Because synthetic analogs exhibit significantly higher potencies and prolonged half-lives compared to endogenous alpha-melanocyte-stimulating hormone (α-MSH), researchers must precisely calculate concentration profiles to avoid receptor saturation or non-specific receptor crosstalk in experimental models.
To maintain reproducibility across experimental trials, researchers cataloging the effects of a melanocortin receptor agonist rely on standardized mass-to-volume metrics. Variations in peptide batch mass, diluent purity, and delivery systems can alter the observed biological response, underscoring the necessity of using high-purity, analytical-grade compounds sourced from verified facilities.
Melanotan peptides represent synthetic cyclic and linear derivatives of α-MSH designed to resist rapid enzymatic degradation by serine proteases and endopeptidases. The primary sequence of endogenous α-MSH is Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. Through strategic amino acid substitutions, researchers synthesized analogs with vastly increased biological stability and altered receptor subtype selectivity.
Melanotan I (Afamelanotide) is a linear 13-amino-acid peptide characterized by the replacement of Met4 with Nle4 (Norleucine) and L-Phe7 with D-Phe7. This structural modification enhances resistance to oxidative inactivation and dramatically prolongs its binding half-life at the melanocortin-1 receptor (MC1R).
Conversely, Melanotan II reagent is a shortened, lactam-bridged cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. The constrained cyclic structure limits conformational flexibility, yielding high affinity across multiple melanocortin receptor subtypes including MC1R, MC3R, MC4R, and MC5R. This pan-agonist profile accounts for the broader range of physiological signaling pathways observed during preclinical administration compared to linear analogs.
The primary objective of evaluating a Melanotan dose in cell-based assays is to analyze signal transduction downstream of MC1R. MC1R is a canonical 7-transmembrane G-protein coupled receptor (GPCR) predominantly expressed on the cell membrane of epidermal melanocytes. Binding of an agonist triggers the activation of membrane-bound adenylyl cyclase via the Gαs subunit.
Activated adenylyl cyclase catalyzes the conversion of intracellular adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Rising intracellular cAMP levels activate Protein Kinase A (PKA), which subsequently phosphorylates the cAMP response element-binding protein (CREB) transcription factor family.
Phosphorylated CREB drives the transcriptional upregulation of Microphthalmia-associated Transcription Factor (MITF), the master regulator of melanogenesis. MITF increases the transcription of rate-limiting melanogenic enzymes, specifically tyrosinase, tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT/TYRP2). This cascade accelerates the synthesis of dark, UV-protective eumelanin over the lighter pheomelanin pigment, providing a clear biological readout for researchers evaluating agonist efficacy in cutaneous tissue models.
In peer-reviewed rodent research, researchers administer synthetic melanocortins via subcutaneous (SC) or intraperitoneal (IP) injection routes to evaluate systemic responsiveness, pigmentary changes, and metabolic effects. Across published rodent literature, daily experimental dosing protocols for Melanotan II typically range between 0.05 mg/kg and 1.0 mg/kg of body mass in C57BL/6 mouse models.
In vitro assays focusing on competitive receptor binding and cAMP accumulation utilize nanomolar concentrations. Studies assessing MC1R activation frequently apply concentrations ranging from 0.1 nM to 10 nM, where Melanotan II demonstrates sub-nanomolar EC50 values for cAMP induction. Microscopic analysis of cultured human melanocytes treated within these concentration windows reveals significant upregulation of dendritic branching and intracellular melanosome density.
Investigators should note that exceeding recommended preclinical dose thresholds in animal models often leads to non-selective receptor engagement. At elevated micromolar ranges, cross-reactivity with MC3R and MC4R in the central nervous system can trigger unintended physiological responses, including transient blood pressure shifts, altered feeding behavior, and involuntary stretching behavior, which may confound baseline study data.
When designing melanocortin research protocols, investigators frequently compare Melanotan derivatives against related peptides in the same structural class. The three most commonly evaluated compounds include Melanotan I (Afamelanotide), Melanotan II, and PT-141 (Bremelanotide). Understanding their distinct receptor binding profiles is essential when selecting the appropriate compound and determining an experimental Melanotan dose.
Melanotan I functions as a highly selective agonist at MC1R, making it the preferred compound for isolated cutaneous pigmentation studies where central melanocortin signaling (MC3R/MC4R) must be minimized. In contrast, Melanotan II acts as a potent pan-agonist across MC1R, MC3R, MC4R, and MC5R, producing concurrent effects on skin pigmentation, central energy homeostasis, and autonomic pathways. Bremelanotide (PT-141), a metabolite derivative of Melanotan II possessing a hydroxylated C-terminus, retains high affinity for MC3R and MC4R but demonstrates lower comparative activity at MC1R, shifting its research utility toward neuroendocrine and vascular pathways rather than melanogenesis.
To explore the structural and functional nuances between these analogs in greater detail, investigators can refer to our comprehensive Melanotan I vs Melanotan II comparison in the PX1 Research library hub.
Lyophilized peptide reagents must be reconstituted with sterile, laboratory-grade diluents prior to experimental administration. Bacteriostatic Water for Injection (0.9% benzyl alcohol) or sterile normal saline (0.9% NaCl) are the standard solvent systems utilized in preclinical protocols to prevent bacterial proliferation during multi-dose study timelines.
To establish a precise Melanotan dose concentration, researchers utilize volumetric standard formulas. For example, dissolving a 10 mg vial of lyophilized Melanotan II in 2.0 mL of bacteriostatic water yields a final concentration of 5.0 mg/mL (or 5000 µg/mL). If a rodent model protocol calls for a dose of 100 µg, the required injection volume is calculated as follows:
Volume (mL) = Required Mass (mg) / Solution Concentration (mg/mL) = 0.10 mg / 5.0 mg/mL = 0.02 mL (20 µL). Accurate dispensing requires calibrated, high-precision micro-pipettes or specialized low-dead-space insulin syringes to minimize volumetric transfer errors. For additional guidance on solvent compatibility and concentration math, reference our dedicated peptide reconstitution guide.
Synthetic peptides are vulnerable to chemical degradation via hydrolysis, oxidation, and aggregation if subjected to improper environmental conditions. In its lyophilized state, Melanotan should be stored in a temperature-controlled freezer at -20°C or -80°C, protected from light exposure, to maintain structural integrity for extended periods.
Upon reconstitution, the peptide's liquid state significantly increases its susceptibility to cleavage. Reconstituted solutions should be maintained under refrigeration at 2°C to 8°C and used within 30 days. Repeated freeze-thaw cycles must be strictly avoided, as the physical stress of ice crystal formation disrupts tertiary structure and leads to peptide aggregation.
For long-term storage of reconstituted aliquots, researchers should divide the master solution into single-use, polypropylene micro-centrifuge tubes and store them at -80°C. Micro-tubes should be thawed once immediately prior to assay execution, ensuring consistent potency across longitudinal study timelines.
The validity of preclinical experimental data depends entirely on the chemical purity and analytical verification of the research peptide. Impurities such as truncated peptide fragments, unreacted synthesis reagents, or residual organic solvents can produce cytotoxic effects in cell culture or alter receptor binding kinetics.
PX1 Research enforces rigorous quality control protocols on every production lot. Purity is characterized using Reverse-Phase High-Performance Liquid Chromatography (HPLC purity analysis) paired with Electrospray Ionization Mass Spectrometry (ESI-MS) to verify absolute identity and molecular weight.
Additionally, because bacterial lipopolysaccharides (LPS) induce severe inflammatory responses in animal models and alter cell signaling pathways, research peptides must undergo Limulus Amebocyte Lysate (LAL) testing. PX1 Research guarantees endotoxin thresholds below 0.01 EU/mg, protecting experimental integrity in cell culture and animal models.
When procuring compounds from a supplier, research institutions require complete lot traceability and batch-specific verification. Academic and corporate laboratories evaluating suppliers should mandate public access to independent, third-party Certificates of Analysis (COAs) for every unique lot number.
PX1 Research manufactures all compounds in cGMP-compliant, USA-based facilities adhering to ISO 9001 and ISO 17025 quality management standards. Every product shipped to laboratory client sites contains batch-matched analytical documentation detailing purity percentages, mass spectral verification, and endotoxin assay results.
To maintain uninterrupted research schedules, PX1 Research provides same-day dispatch from fulfillment hubs in California and Arizona for orders placed Monday through Friday. Principal investigators managing large-scale screening projects can browse our full catalog of synthetic peptides or establish a dedicated bulk research account for specialized laboratory procurement.
What is the standard concentration calculation for a Melanotan dose in rodent models?
In rodent literature, experimental Melanotan doses range from 0.05 mg/kg to 1.0 mg/kg of body weight. Volumes are calculated using the formula: Volume = Target Mass (mg) / Solution Concentration (mg/mL).
How do Melanotan I and Melanotan II compare regarding receptor selectivity?
Melanotan I (Afamelanotide) is highly selective for the MC1R receptor, primarily regulating pigmentation. Melanotan II is a cyclic pan-agonist that activates MC1R, MC3R, MC4R, and MC5R, inducing central metabolic and autonomic responses alongside melanogenesis.
What diluents are used to reconstitute Melanotan for laboratory research?
Preclinical protocols utilize sterile Bacteriostatic Water for Injection (0.9% benzyl alcohol) or sterile 0.9% Normal Saline under aseptic laboratory conditions.
What are the storage requirements for lyophilized vs reconstituted Melanotan?
Lyophilized powder should be stored at -20°C or -80°C away from light. Once reconstituted, solutions should be kept refrigerated at 2°C to 8°C for up to 30 days, avoiding repeated freeze-thaw cycles.
How is purity verified for PX1 Research Melanotan peptides?
Every lot undergoes analytical verification via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to ensure ≥99% purity, alongside Mass Spectrometry (MS) to confirm molecular weight.
What endotoxin threshold is acceptable for in vitro cell culture assays?
PX1 Research enforces endotoxin limits below 0.01 EU/mg (verified by LAL assay) to ensure compounds do not induce inflammatory artifacts or cytotoxicity in cell culture or animal models.
Are Melanotan peptides sold by PX1 Research approved for human consumption?
No. All products supplied by PX1 Research are strictly designated for laboratory research use only (RUO) and preclinical testing. They are not for human or animal therapeutic, diagnostic, or clinical use.
How does Melanotan II differ from Bremelanotide (PT-141)?
Melanotan II acts strongly on both MC1R and central receptors (MC3R/MC4R). PT-141 is a structural derivative optimized for MC3R and MC4R activity with reduced comparative MC1R affinity, making it less active in cutaneous melanogenesis pathways.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.